OncoMatch/Clinical Trials/NCT06414148
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Is NCT06414148 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Epcoritamab and Epcoritamab, lenalidomide and rituximab for relapsed/refractory large b-cell lymphoma.
Treatment: Epcoritamab · Epcoritamab, lenalidomide and rituximab — This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 CAR T-cell therapy received
Received...anti-CD19 CAR T-cell therapy as the most recent large B-cell lymphoma treatment
Excluded: CD20 negative
Patients whose lymphoma is known to be CD20 negative on the most recent biopsy prior to CAR T-cell therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD19 CAR-T cell therapy — most recent large B-cell lymphoma treatment
Received...anti-CD19 CAR T-cell therapy as the most recent large B-cell lymphoma treatment
Cannot have received: bispecific antibody targeting CD3 and CD20
Progression or relapse within 3 months after a regimen containing a bispecific antibody targeting CD3 and CD20
Lab requirements
Blood counts
Adequate haematological function documented within 7 days prior to randomisation
Kidney function
Adequate renal function, documented within 7 days prior to randomisation
Liver function
Adequate hepatic function documented within 7 days prior to randomisation
Cardiac function
Adequate cardiac function
Adequate haematological function documented within 7 days prior to randomisation; Adequate cardiac function; Adequate renal function, documented within 7 days prior to randomisation; Adequate hepatic function documented within 7 days prior to randomisation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify